<DOC>
	<DOCNO>NCT00107718</DOCNO>
	<brief_summary>This Phase II study design evaluate anti-tumor activity three dose group SB-485232 ( 0.01 , 0.1 , 1.0 mg/kg/day ) administer intravenously single agent subject previously untreated metastatic melanoma .</brief_summary>
	<brief_title>Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Inclusion criterion : Patients must melanoma spread beyond original location yet treat . Tissue spread melanoma test confirm melanoma . Exclusion criterion : Patients hepatitis HIV infection . Taking corticosteroid . Patients primary site occular melanoma patient melanoma brain .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>IL-18</keyword>
	<keyword>Phase 2</keyword>
	<keyword>melanoma</keyword>
	<keyword>treatment naive</keyword>
</DOC>